Challenges to Developing New Vaccines and Improving Existing Platforms
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 30 April 2025 | Viewed by 367
Special Issue Editor
2. Virology, Veterinary Sciences Division, Agri-Food and Biosciences Institute, Belfast BT4 3SD, UK
Interests: pathogenic mechanisms of RNA viruses (morbilliviruses, respiratory syncytial virus, coronavirus); recombinant vaccine design; genetic markers of virus susceptibility and assessment in small/large animal models; paramyxoviruses; pathogenic mechanisms of measles virus; morbilliviruses; respiratory syncytial virus; coronavirus; vaccine design; vaccination
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The science community faces significant challenges in developing new vaccines and enhancing existing vaccine platforms for infectious diseases and cancer. This Special Issue will address the following aspects of vaccines and their development:
- Vaccine delivery for human and animal species for infectious diseases and cancer.
- Advances in vaccine design that provide broad protection and stimulate humoral and cellular immunity.
- Combining inactivated and subunit vaccines with long-acting adjuvants to maximize their effectiveness.
- Development of novel assays, e.g., omics-based approaches, to evaluate comprehensive and early responses to vaccination.
- Overcoming obstacles in developing flavivirus vaccines, e.g., dengue viruses, addressing virus serotypes, and preventing antibody-dependent enhancement.
We eagerly anticipate your contributions.
Prof. Dr. S. Louise Cosby
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- infectious disease
- cancer vaccines
- humoral and cellular immunity
- flaviviruses vaccines
- inactivated and subunit vaccines
- novel assays
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
